Cancer vaccine pp65 - Immunomic Therapeutics/Duke University

Drug Profile

Cancer vaccine pp65 - Immunomic Therapeutics/Duke University

Alternative Names: CMV pp65-LAMP mRNA-loaded dendritic cells; Cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells; LAMP + pp65 DC; pp65-flLAMP DC; pp65-shLAMP DC

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duke University Medical Center; Immunomic Therapeutics
  • Developer Duke University Medical Center; National Cancer Institute (USA); University of Florida
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Interleukin 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma

Most Recent Events

  • 15 May 2017 Duke University has patent protection for cytomegalovirus immunotherapy plaform
  • 04 Oct 2016 Immunomic Therapeutics in-licenses NTC’s RNA-OUT™ and HyperGro™ technology from Nature Technology Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top